InspireMDNSPR
Recorded

InspireMD 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration23 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

As a reminder, this conference call is being recorded. At this time, I would like to turn the conference over to Ms. Alexandra Grossman with LifeSci Advisors. Ma'am, please begin. Thank you.

Adam GrossmanDirector and Relationship Manager

During this call, management will make forward-looking statements, which are based upon management's current expectations, beliefs, and projections, many of which, by their nature, are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed in such forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K, quarterly report on Form 10-Q, any updates in its current reports on Form 8-K, as well as in InspireMD's press release that accompanies this call, particularly the cautionary statements made in it. During the call today, the company may also discuss certain non-GAAP financial measures.

Adam GrossmanDirector and Relationship Manager

For a more detailed discussion of these non-GAAP financial measures and historical reconciliation to the most closely comparable GAAP measures, please refer to the company's earnings release. This call contains time-sensitive information that is accurate only as of today, November 12, 2026. Except as required by law, InspireMD disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Marvin Slosman, Chief Executive Officer.

Marvin SlosmanCEO

Marvin, please go ahead. Thank you, and good afternoon, everyone.

Marvin SlosmanCEO

The third quarter marked a turning point for InspireMD, and today I am pleased to discuss what we believe is one of the most significant milestones in the company's history. I first want to briefly address the financing announcement we issued today. As you saw in a separate press release issued this afternoon, we have announced a proposed underwritten equity public offering. This financing is intended to support the next phase of our growth, including the full commercialization of CGuard Prime in the U.S. and the broader execution of our strategic priorities. Given that the offering process is ongoing, there are SEC-imposed limitations on what can be discussed beyond the information included in today's announcement. Thus, we are not commenting on the potential size, pricing, timing, and other terms of the transaction during this call.

Marvin SlosmanCEO

We appreciate your understanding and look forward to providing additional information through the appropriate public disclosures as it becomes available. As I just mentioned, today I'm pleased to discuss what we believe is one of the most significant milestones in our company's history. With FDA approval of our CGuard Prime TransCarotid Stent System for TCAR procedures, we are returning to the U.S. market with our next-generation carotid implant, supported by a strong body of clinical evidence, which we believe positions us to significantly expand our market penetration and pursue our mission to lead the carotid revascularization field. Let me take a moment to thank the entire team at InspireMD, as well as the physician partners who have been instrumental in this approval. This return to the U.S. market represents more than a regulatory achievement.

Marvin SlosmanCEO

We believe it reinforces the clinical value of our CGuard Prime carotid stent as the best-in-class device for treating patients and helping prevent stroke, and it marks the beginning of the next phase of InspireMD's evolution, shifting our focus back to growing our commercial presence in the U.S. market. As a reminder, our next-generation CGuard implant has demonstrated unmatched clinical evidence and results in over 75,000 procedures globally, and we believe these clinical results establish a new standard of care in stroke prevention. When we spoke to you last quarter, we outlined a clear set of priorities centered on advancing our regulatory programs to approvals in the U.S., strengthening our international business, enhancing our CAS delivery system, and aligning our organization and cost structure. We've made meaningful progress against each of these objectives.

Marvin SlosmanCEO

The approval of the CGuard Prime TransCarotid Stent System was supported by the CGUARDIANS II pivotal trial, which demonstrated 100% acute device success among 50 patients with no deaths, strokes, or myocardial infarctions through 30 days, and complete stent patency at 30 days amongst evaluated patients. We believe these results reinforce the clinical value of our CGuard implant and its proprietary MicroNet mesh technology. Our value proposition has always been centered on treating the lesion and providing durable protection against stroke. This TCAR indication expands our U.S. addressable market by approximately 40,000 annual procedures, effectively doubling our opportunity, which we plan to immediately pursue with a world-class commercial team on the field ready to execute. It also enables an indication for use of our implant in TCAR, a major carotid revascularization approach.

Marvin SlosmanCEO

Our strategy is to make CGuard available across both TCAR as well as transfemoral CAS procedures to address the broad range of patients and physician needs. We believe we were the first company to focus on the entirety of the carotid field with an implant-first approach, building on the clinical evidence derived from our mesh-protected platform. With this approval, our focus now shifts to commercial execution. As we commence U.S. sales, we intend to build on the base and momentum of our account approvals, physician awareness, and enthusiasm we've developed for this technology. We will continue to follow our commercial playbook with a disciplined and direct approach to sales growth. Over the past few months, we prepared for this return with an emphasis on commercial readiness, physician engagement, training, and clinical support.

Marvin SlosmanCEO

We strengthened our leadership with the appointment of Kathy Kennedy as Senior Vice President of Global Sales and Marketing, along with the promotion and addition of several key leaders on our engineering, clinical, regulatory, and operations functions to support this launch and prepare for future approvals and platform enhancements. We see this approval as only the beginning in the pursuit of our mission to lead this important and growing segment of vascular medicine with a comprehensive set of devices supported by clinical evidence. Sustained success will depend on consistent execution, physician confidence, and our ability to translate clinical differentiation into routine use, which we believe is achievable. Our international business continued to grow, with third quarter revenues increasing approximately 9% year-over-year to $2.2 million.

Marvin SlosmanCEO

Through the first nine months of 2026, international revenue increased approximately 24% to $6.6 million, reflected continued adoption of our CGuard platform across our markets. While reported U.S. revenue remained affected by our absence from the market following the May voluntary recall of CGuard Prime 135 delivery system, international demand continues to demonstrate the underlying appeal of our implant technology. Beyond TCAR, we continue to advance programs designed to broaden our carotid intervention portfolio. Our original CGuard carotid stent system for CAS remains under FDA review. We believe this platform, with its extensive history of international clinical sales and over 75,000 patients, could complement our offering and further expand access to our technology, subject to FDA approval. For the CGuard Prime 135 CAS delivery system, we have implemented design enhancements following the voluntary recall.

Marvin SlosmanCEO

Validation and performance testing are underway, and we currently anticipate an FDA submission before year's end. We continue to work toward reentry of this platform in the first half of 2027, subject to regulatory review and approval. Enrollment is progressing in our CGUARDIANS III pivotal trial, evaluating our proprietary SwitchGuard neuroprotection system for TCAR procedures. We believe SwitchGuard represents an opportunity to complement our implant with a comprehensive set of proprietary tools and technology to expand our procedural reach. As a next step in expanding our capabilities into TCAR, we plan to introduce a proprietary micro puncture kit designed to support vascular access, which we currently expect in a planned release early Q1 2027. Together, these initiatives reflect our goal of building a more comprehensive carotid intervention platform, offering physicians a broad set of solutions across both TCAR and CAS.

Marvin SlosmanCEO

We remain focused on aligning our resources around the highest priority of regulatory and commercial opportunities. During the third quarter, we implemented a workforce reduction of approximately 20%, which we expect will better align our resources with key product development, regulatory, and clinical commercialization priorities while reducing our overall operating expense base. We will remain financially disciplined as we fund our commercial reentry and advance our pipeline. Mike will provide additional details on the financial performance, liquidity, cost structure, and so forth in a few moments. Before turning the call over to Mike, I want to reinforce four key messages. First, FDA approval for TCAR represents a major milestone, returning CGuard Prime to the U.S. market with a next-generation implant and significantly expanding our addressable opportunity. Second, we believe we are positioned to execute on our growth strategy and continue building toward profitability.

Marvin SlosmanCEO

Third, we are moving into a growth phase focused on commercial execution with an experienced team and a disciplined approach to driving physician adoption. Fourth, we continue to advance a differentiated portfolio across TCAR and CAS, including the original CGuard system, the enhanced Prime 135 delivery platform, SwitchGuard, and complementary procedural technologies. Finally, we have taken meaningful steps to streamline our global operations and align our cost structure with these priorities. We recognize that important work remains ahead of us, but with a differentiated implant, a compelling clinical evidence base, an expanding product portfolio, and a more focused organization, we believe InspireMD is well-positioned for its next phase. With that, I will turn the call over to Mike to review the third quarter financials.

Mike LawlessCFO

Mike, go ahead. Thank you, Marvin.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day